Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 15/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1288296 | 0.83 | PIN1 (0.38) | PIN1PIM3ALDH1A1GAAHPGD | |
| SCHEMBL10449200 | 0.83 | PIN1 (0.38) | PIN1PIM3ALDH1A1GAAHPGD | |
| SCHEMBL1288298 | 0.83 | PIN1 (0.38) | PIN1PIM3ALDH1A1GAAHPGD | |
| SCHEMBL10024798 | 0.81 | PIN1 (0.37) | PIN1ALDH1A1 | |
| SCHEMBL1204064 | 0.80 | PIN1 (0.38) | PIN1TXNRD1ALDH1A1GAA | |
| SCHEMBL10321154 | 0.79 | PIN1 (0.39) | PIN1ALDH1A1GAAHPGD | |
| SCHEMBL10320947 | 0.79 | PIN1 (0.39) | PIN1ALDH1A1GAAHPGD | |
| SCHEMBL10320949 | 0.79 | PIN1 (0.39) | PIN1ALDH1A1GAAHPGD | |
| SCHEMBL10320625 | 0.79 | PIN1 (0.39) | PIN1ALDH1A1GAAHPGD | |
| SCHEMBL11753029 | 0.79 | PIN1 (0.44) | PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2543669-A2 | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation | Boehringer Ingelheim International GmbH (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2009019205-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | disclosed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007090844-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, REN, DHPS | PIN1 460/4885PIM3 3833/4885TXNRD1 2218/4885 |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, DHPS, DPYD | PIN1 242/4885PIM3 4077/4885TXNRD1 2365/4885 |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | DHPS, PKD1, AQP4 | PIN1 237/4885PIM3 3665/4885TXNRD1 2159/4885 |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, REN, DHPS | PIN1 460/4885PIM3 3833/4885TXNRD1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.